INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• CAR-T Reimbursement In The US: ZS Separates Myths From Reality

  Learn about the treatment landscape today from surveys collected at CAR-T treatment centers across the U.S. and  discussions with payers and treatment centers about CAR-T reimbursement realities.

• Commercial-Scale Strategies For Cell And Gene Therapy Drug Manufacturers

  Architecting a connected cell and gene therapy organization is critical, whether your goal is to stand alone or with another business. Building this structure starts with defining roles and acquiring talent, then establishing an effective commercial model.

• Pricing Strategies For Cell And Gene Therapy

  Today, fewer than 25% of eligible patients benefit from cell and gene therapies. Expanding the impact of these therapies must start early in their development as you plan your network strategy and design flexible contracts with payers and providers. 

• Allogeneic Cell Therapy Results: Delving A Little Deeper

  Poseida's CEO explains that the allogeneic cell therapy data we have seen from others has been uninspiring, but the natural follow up question is, “What about those data has fallen short, and what are the likely causes for those results?” The answer is multi-faceted.

• Modernizing Your Cell & Gene Therapy Manufacturing Operations

  What requirements should cell and gene therapy developers meet to successfully bring innovative therapies to market?

• Effective Medical Communications During CGT Clinical Trials

  Medical communications help crystalize the nuances of cell and gene therapies for patients and healthcare providers. For a successful cell or gene therapy launch, you'll need to draw attention to stakeholders early in clinical trials to effectively inform them of the value of the therapy in development. This article shares key tips for an effective strategy.

• Gene Therapies For All: Getting Treatments To Everyone In Need

  We explore the role gene therapy manufacturers play in addressing the challenge of slow adoption of these therapies to help pave the way for the future.

• CAR-T & Beyond: CGTs In Development In 2022

  There's more going on in cell and gene therapy work than CAR-T. This article reviews the main cell technologies currently being developed in clinical research, including examples of studies being conducted, developers, modes of action, and benefits of the different types of cell therapies. The article also shares insight on how to avoid pitfalls and prepare for rapid market uptake.

• CGT, The Value Chain, And The Central Role Of The Patients

  This article details three ways patients’ perspective can be incorporated across the CGT value chain.

• Maximizing The Project Managers Sphere Of Influence In Life Sciences

  Learn how a project management process that works across disciplines can help coach, improve, and inspire others in that method to help them get the business value they need.